Salute e Benessere

MGI Enters Strategic Partnership with Prepaire Labs to Advance Drug Discovery…

Powered by MGI's proprietary DNBSEQTM technology, T20 is a fully automated genetic sequencer that has achieved major technological breakthroughs and made waves in the global industry for lowering genome sequencing cost to sub-$100 per genome. Designed to meet the most challenging sequencing scenarios, it covers all high-throughput sequencing needs in scientific research and clinical applications, including WGS, WGBS, stLFR, single-cell sequencing, Stereo-seq and more. Powered by MGI's...
PR Newswire
05/02/2024

Personnel changes in the Exyte management: Mark Garvey and Elena Bashkeeva are…

Exyte CEO Dr. Wolfgang Büchele states, "Mark Garvey is an expert within the global high-tech industries. He has played a crucial role in shaping the strategic development and success of Exyte in his previous roles. Under his leadership, the Global Business Unit Advanced Technology Facilities has progressively expanded its leading role in its markets. I look forward to further collaborate with him." Exyte CEO Dr.Wolfgang Büchelestates, " Mark Garveyis an expert within the global…
PR Newswire
05/02/2024

Global Medical Device Testing Market Revenue to Surpass $15.84 Billion by 2030…

Request Sample PDF of the Report: https://www.kingsresearch.com/request-sample/medical-device-testing-market-147 Request Sample PDF of the Report: https://www.kingsresearch.com/request-sample/medical-device-testing-market-147 Trending Now: UL Solutions Expands Presence with Medical Device Testing Launch inMichigan InOctober 2023, UL Solutions introduced a range of medical device testing services at theirRochester Hillslaboratory inMichigan. These new services aim to...
PR Newswire
05/02/2024

HAMILTON BEACH BRANDS HOLDING COMPANY ANNOUNCES ACQUISITION OF HEALTHBEACON PLC

"We expect growth opportunities to be driven by the rapidly evolving development of in-home healthcare management tools, including Remote Therapeutic Monitoring systems. This acquisition combines our trusted brand name and our leadership in innovation, engineering, and product development with HealthBeacon's leadership in digital capabilities and patented technologies. We are very excited to welcome HealthBeacon's outstanding team of highly skilled employees as we work together to scale the…
PR Newswire
05/02/2024

Novo Nordisk to acquire three fill-finish sites from Novo Holdings A/S in…

Bagsværd, Denmark, 5 February 2024– Novo Nordisk today announced that the company has agreed to acquire three fill-finish sites from Novo Holdings A/S (Novo Holdings) in connection with a transaction where Novo Holdings has agreed to acquire Catalent, Inc. (Catalent), a global contract development and manufacturing organisation headquartered in Somerset, New Jersey (US). Novo Nordisk and Catalent have a long-standing collaboration.The acquisition of the filling sites is aligned with Novo...
Nasdaq GlobeNewswire
05/02/2024

mAbxience and Biosidus Sign CDMO Agreement for the Manufacture of Agalsidase…

This agreement marks a significant milestone for both mAbxience and Biosidus, as it represents a strategic advance in their respective areas of expertise. In addition, mAbxience strengthens its position in the CDMO sector, demonstrating its ability to collaborate in the development and manufacture of complex, high-value treatments. For Biosidus, this agreement means a significant milestone in its path to increase its impact in the global pharmaceutical industry, being the first biosimilar…
PR Newswire
05/02/2024

New Indication Approved for Verdye (Indocyanine Green for Injection, ICG) for…

The presence of lymphatic metastases is an important prognostic factor for the survival of breast cancer. Sentinel lymph node biopsy (SLNB) continues to be a fundamental component of early breast cancer detection and is the current standard of care to help determine whether cancer has spread to the lymph nodes. With the approval of ICG for breast SLNB, surgeons now have an alternative to using Technetium (99mTc) radio-labelled colloids with blue dyes (BD) to visualise lymph nodes...
PR Newswire
05/02/2024

Wingderm® "Dual Innovation, Infinite Possibilities" Global Distributor…

Renuva® has won the favor of many partners since its launch. Carol Ren, Vice President of Wingderm®, pointed out that Renuva® has been upgraded in various aspects such as the improved Rolling Tips adopt magnetic sensing technology, and the new GrowTip specifically for the application in hair growth. Through these improvements, Renuva® will further enhance the operation convenience and meet the individual needs of beauty seekers. Renuva® has won the favor of many partners since its launch...
PR Newswire
05/02/2024

GCC Dental Equipment Sector Poised for Robust Growth, Market to Reach $821.8M by…

The dental equipment market in the GCC is undergoing a transformation, driven by groundbreaking technological advancements and strong government initiatives. Key strategies like the UAE's Dubai Health Strategy 2021 and Kuwait's innovative healthcare financing mechanisms are laying a robust foundation for the sector's growth, demonstrating a strong commitment to enhancing dental healthcare services in the region. The dental equipment market in the GCC is undergoing a transformation, driven by...
PR Newswire
05/02/2024

Implantica presents the fourth quarter 2023 on February 16 at 15:00 CET

If you wish to participate via webcast, please use the following link: If you wish to participate via webcast, please use the following link: If you wish to participate via teleconference, please register on the link below. After registration, you will be provided the phone number and a conference ID to access the conference. Speakers: For further information, please contact: Nicole Pehrsson, Investor Relations Telephone (CH): +41 (0)79 335 09 49nicole...
PR Newswire
05/02/2024

Press Release: Peer support, flexible work arrangements, salary for a year…

Peer support, flexible work arrangements, salary for a year: Sanofi launches global program for employees affected by cancer and critical illnessesParis, February 5, 2024. Sanofi today launches'Cancer & Work: Acting Together', a global program to support Sanofi employees whose lives are impacted by cancer and other critical illnesses. This program covers all Sanofi employees in the world if they are diagnosed with cancer or critical illnesses*. It providessocial, emotional...
Nasdaq GlobeNewswire
05/02/2024

SIFI ANNOUNCES THE ESTABLISHMENT OF A JOINT VENTURE IN THE UNITED ARAB EMIRATES

The JV will be based in Dubai and initially focus on the United Arab Emirates ("UAE"), expanding its commercial reach to Bahrein, Oman, Qatar, Kuwait, and the Kingdom of Saudi Arabia as a second step. Approximately 100.000 cataract surgeries are performed each year across these Countries with an annual growth rate of 3.0%, with almost 50% Premium IOLs. The JV will be based inDubaiand initially focus on theUnited Arab Emirates("UAE"), expanding its commercial reach to…
PR Newswire
05/02/2024

From Riyadh to Rafah: KSrelief Brings Hope to Gaza

His Excellency, Dr. Abdullah Al Rabeeah, Supervisor General of KSrelief, said, "The complexity of delivering aid to Gaza is significant, but not impossible. Through immediate solutions such as implementing advanced security checks and bolstering critical infrastructure, we can ensure that aid reaches the Gaza Strip and is expedited to those in desperate need. His Excellency, Dr.Abdullah Al Rabeeah, Supervisor General of KSrelief, said, "The complexity of delivering aid toGazais...
PR Newswire
05/02/2024

Valneva Announces Sale of Priority Review Voucher for $103 Million

Saint-Herblain (France), February 5, 2024– Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced it sold the Priority Review Voucher (PRV) it received from the U.S. Food and Drug Administration (FDA) for $103 million (€95 million). The Company was awarded a tropical disease PRV in November 2023 1following U.S. FDA approval of IXCHIQ ®, Valneva's single-dose, live-attenuated vaccine indicated for the prevention of disease caused by chikungunya...
Nasdaq GlobeNewswire
05/02/2024

Ultimovacs Receives FDA Fast Track Designation for UV1 Cancer Vaccine for the…

Fast Track designation is granted for UV1 in combination with ipilimumab and nivolumab for the treatment of patients with unresectable malignant pleural mesothelioma to improve overall survivalThe designation was granted by the U.S. Food and Drug Administration (FDA) based on results from the randomized Phase II clinical trial NIPU, which showed improved overall survival with UV1 vaccination as an add-on to ipilimumab and nivolumab immunotherapyUV1 as add-on therapy had previously...
Nasdaq GlobeNewswire
05/02/2024

Bridge to Life Achieves ISO 13485:2016 Certification, Reinforcing Commitment to…

"We are thrilled to have achieved ISO 13485:2016 certification" said Don Webber, CEO of Bridge to Life. "This accomplishment is a testament to our team's dedication to providing the highest quality products and services to our customers across the global markets we currently serve." "We are thrilled to have achieved ISO 13485:2016 certification" saidDon Webber, CEO of Bridge to Life. "This accomplishment is a testament to our team's dedication to providing the…
PR Newswire
05/02/2024

MGI: Closing the Cancer Care Gap with the Power of Precision Oncology

In this new era in precision oncology, researchers like Dr. Marie-Laure Yaspo from ALACRIS Theranostics ("ALACRIS") and Dr. Xuan Gao and Dr.Huan Fang from GenePlus are working towards closing the care gap with evidence-based strategies in cancer control along the care continuum, from prevention to treatment, with help from MGI's cutting-edge life science technologies. In this new era in precision oncology, researchers like Dr. Marie-Laure Yaspo from ALACRIS Theranostics…
PR Newswire
04/02/2024

Accord Healthcare partners with ITN Business for World Cancer Day to explore how…

The reality is every two minutes someone in the UK is diagnosed with cancer, with 1 in 2 people being diagnosed with some form of cancer during their lifetime[1]. The reality is every two minutes someone in the UK is diagnosed with cancer, with 1 in 2 people being diagnosed with some form of cancer during their lifetime[1]. Accord's film showcases how we are helping to tackle cancer highlighting our heritage as an oncology medicines company with our generic portfolio and how the company is...
PR Newswire
04/02/2024

Monthly information on share capital and company voting rights

(Article 223-16 of General Regulation of the French financial markets authority) PARIS, Feb.02, 2024(GLOBE NEWSWIRE) -- Listing market: Euronext GrowthISIN code: FR0010425595DateTotal number of shares in the capitalTotal number of votingrights 01/31/202471,751,20177,686,818 For further information on Cellectis, please contact: Media contact: Pascalyne Wilson, Director, Communications, +33 (0)7 76 99 14 33, media@cellectis.comPatricia...
Nasdaq GlobeNewswire
02/02/2024

Casino Group: Update on the conditions precedent to the financial restructuring

Update on the conditions precedent to the financial restructuring Paris, 2 February 2024Casino announces that the anti-trust authorities of Serbia, Northern Macedonia, Morocco and Kosovo issued decisions authorising, under merger control, the acquisition of control of the Group as part of the financial restructuring by the consortium (composed of EP Equity Investment III s.à r.l., Fimalac and Attestor), it being specified that the consortium's acquisition vehicle will be controlled by EP...
Nasdaq GlobeNewswire
02/02/2024

BioSenic raises €500,000 in private placement of new shares with established new…

PRESS RELEASE – REGULATED INFORMATION NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN, SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH IT WOULD BE UNLAWFUL TO DO SO.Mont-Saint-Guibert, Belgium, 2 February 2024, 17:30 CET –BioSenic (Euronext Brussels and Paris: BIOS), the clinical-stage company specializing in serious autoimmune and inflammatory diseases and cell therapy, today...
Nasdaq GlobeNewswire
02/02/2024

Neuromodulation Market Worth $11.0 Billion | MarketsandMarkets™.

Browse in-depth TOC on "Neuromodulation Market" Browse in-depth TOC on "Neuromodulation Market" 195 - Tables 39 - Figures 210 - Pages Neuromodulation Market Scope: Internal neuromodulation accounted for the largest share of the neuromodulation market, by type segment, in 2022. The global neuromodulation market is segmented into internal neuromodulation and external neuromodulation based on type. In 2022, internal neuromodulation dominated the global...
PR Newswire
02/02/2024

Clean Beauty and Male Grooming Products Drive Jojoba Oil Market Growth, Valued…

Request Exclusive Sample Report: Jojoba Oil Industry Strategic Insights, https://www.futuremarketinsights.com/reports/sample/rep-gb-18895 Request Exclusive Sample Report: Jojoba Oil Industry Strategic Insights , https://www.futuremarketinsights.com/reports/sample/rep-gb-18895 The clean beauty movement emphasizes products that are free from potentially harmful ingredients such as parabens, sulfates, and synthetic fragrances. The natural composition of jojoba oil aligns...
PR Newswire
02/02/2024

Lumosa Therapeutics and CHI Memorial announce new study for acute stroke

Unlike the current U.S. FDA-approved drug, tissue plasminogen activator (t-PA), which must be administered within 4.5 hours after onset of stroke symptoms, Lumosa's LT3001 breaks down clots while also protecting delicate nerve tissues in the brain. This novel approach greatly extends the stroke treatment window to 24 hours, allowing potential treatment for many more stroke victims. Lumosa and CHI Memorial aim to redefine what is possible in preventing stroke disability and impairment. Unlike...
PR Newswire
02/02/2024
Altri  Comunicati